Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00707993 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 441
- Enrollment target
NCT00707993 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 441 participants.
The verdict
NCT00707993, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 441 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), compared to glipizide in elderly diabetic patients who have not received treatment or are on a single oral medication.
Interventions
- DRUG Glipizide
- DRUG Alogliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 441 participants |
| Start Date | 2008-06 |
| Est. Completion | 2010-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00707993
The ClinicalTrials.gov registry entry for NCT00707993 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 441 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Glipizide is the first listed.
NCT00707993 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00707993 about?
NCT00707993 is a clinical study titled "Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics". The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), compared to glipizide in elderly diabetic patients who have not received treatment or are on a single oral medication.
What is the current status of trial NCT00707993?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 441 participants. The study started on 2008-06. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00707993?
The interventions under investigation include: Glipizide (DRUG), Alogliptin (DRUG).
Who is sponsoring clinical trial NCT00707993?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.